Table 1.
Studies investigating neutrophil chemotaxis in diabetes.
| Study | Animal model/human volunteer type | Chemotaxis phenotypes reported in diabetes |
|---|---|---|
| Studies reporting a decrease in neutrophil chemotaxis in T1D or T2D compared to control | ||
| (48) | HVs + T2D volunteers | ↓ in chemotaxis towards casein and human serum |
| (117) | HVs + 17 children with T1D | ↓ chemotaxis towards Staphylococcus epidermidis & albumin |
| (118) | HVs + those with T2D (mild to severe periodontitis) | No difference between HVs and those with mild periodontitis+T2D. Significant ↓ in severe periodontitis + T2D. Endotoxin activated plasma and fMlp used as chemoattractant |
| (116) | Alloxan treated rat model | ↓ in chemotaxis. Incubating healthy rat neutrophils in diabetic rat plasma also ↓ chemotaxis |
| (119) | HVs+ volunteers with T1D | ↓ chemotaxis towards zymosan-activated plasma. No difference towards fMlp and Escherichia coli supernatant |
| (49) | HVs + people with T1D and T2D | ↓ chemotaxis towards fMlp but no difference towards healthy control serum |
| (55) | Akita mouse (point mutation in Ins2 gene- inability to produce insulin-T1D model) | ↓ chemotaxis towards fMlp and WKYMVm but no difference in random (unstimulated) migration. |
| (120) | Alloxan treated rats | No WT rats used in the study. ↓ chemotaxis towards casein and fMLP in rats with severe compared to mild diabetes |
| (121) | Neutrophils investigated from WT rats incubated in serum from Alloxan treated rats or WT | No difference in chemotaxis towards fMLP or Leukotriene B4. ↓ chemotaxis towards LPS-activated rat sera in diabetic serum group |
| (122) | HVs + people with T2D undergoing tooth extractions | ↓ chemotaxis towards fMLP |
| (51) | HVs + people with insulin dependent diabetes | ↓ chemotaxis towards fMLP |
| (123) | Low dose STZ-treated mice | ↓ chemotaxis towards casein |
| Studies reporting no difference in neutrophil chemotaxis in T1D or T2D compared to control | ||
| (124) | HVs + people with T1D or T2D). Mixture of children and adults in both groups. | No difference in chemotaxis to zymosan activated serum |
| (53) | HVs + those with T2D | No difference in chemotaxis towards fMLP |
| (125) | HVs + people with diabetes and periodontitis | No difference towards zymosan activated serum |
| (126) | HVs + people with T2D and periodontitis | No difference towards zymosan activated serum |
| (127) | HVs + people with T1D or T2D | No difference in chemotaxis towards fMLP |
HVs, Healthy volunteers; fMlp, N-Formyl-methionyl-leucyl-phenylalanine; WT, Wild-type.